Pyramidobacter piscolens

Bacteria
General | Carbohydrate O/F | Substrate utilisation | Enzymes | Metabolites | Antibiotics

Overview

  • Pyramidobacter piscolens is a Gram-negative, non-spore-forming, strictly anaerobic, non-motile, rod-shaped bacterium. It has been detected in at least 11 gut microbiome compilation studies or metastudies. The DNA G+C content is 59%. Pyramidobacter piscolens is probably a common, although minor, coloniser of the gut. (Downes2009)



  • This organism has been recovered from dental disease, abscesses and human faeces. Pathogenicity status unknown, or very unlikely to be pathogenic. A possible gut commensal.
    • GENERAL CHARACTERISTICS (Downes2009);
    Character Response
  • 💧
  • Bile tolerance:
  • Doesn't tolerate 20% bile
  • 🌡
  • Temperature tolerance:
  • grows at 25℃; grows at 42℃; Grows optimally at 30-37℃.
  • Active enzymes:
  • Gly arylamidase;
    • SPECIAL FEATURES (Downes2009);
    Character Response
  • ✓
  • Metabolites produced:
  • acetate (major); propionate (minor); isobutyrate (minor); succinate (minor); isovalerate; Hâ‚‚S;
  • ✗
  • Metabolites not produced:
  • indole;
  • ✗
  • Nitrate:
  • not reduced
    • RESPONSE TO ANTIBIOTICS (Downes2009);
    Class Active Resistant
  • Penicillins:
  • amoxicillin; ampicillin; penicillin;
  • Cephalosporins:
  • cefoxitin;
  • Tetracyclines:
  • tetracycline;
  • Quinolines:
  • ciprofloxacin;
  • Aminoglycosides:
  • gentamicin;
  • Heterocycles:
  • metronidazole;
  • trimethoprim;
  • Miscellaneous antibiotics:
  • clindamycin;

  • Lagier, J.-C., Armougom, F., Million, M., Hugon, P., Pagnier, I., Robert, C., Bittar, F., Fournous, G., Gimenez, G., Maraninchi, M., Trape, J.-F., Koonin, E. V., La Scola, B., & Raoult, D. (2012). Microbial culturomics: paradigm shift in the human gut microbiome study. Clinical Microbiology and Infection: The Official Publication of the European Society of Clinical Microbiology and Infectious Diseases, 18(12), 1185–1193.

    • Details

    GENERAL
    Lineage Physiology General Growth Tolerances Hydrol./digest./degr.
    Phylum:  Synergistetes Class:  Synergistia Order:  Synergistales Family:  Synergistaceae Genus:  Pyramidobacter Gram stain:  neg O2 Relation.:  strictly anaerobic Spore:  No spore Motility:  Sessile Morphology:  Rod
    Health:  Unknown
    Source:  dental disease, abscesses and human faeces
    DNA G+C(%):  59
    Opt. T:  30-37℃
    Lower T(℃):  25(+)
    High T(℃):  42(+)
    Bile reaction(%):  20(neg)
    		Aesculin:  neg Urea:  neg Gelatin:  neg
    CARBOHYDRATE ACID FORMATION
    Monosaccharide O/F Oligosaccharide O/F Polysaccharide O/F Polyol O/F Other O/F
    Mannose:  neg
    SUBSTRATE ASSIMILATION & UTILISATION
    Monosaccharide util/assim Oligosaccharide util/assim Other carboh. util/assim Amino acid util/assim Organic acid util/assim
    Arabinose:  neg Fructose:  neg Glucose:  neg Mannose:  neg Rhamnose:  neg Xylose:  neg Cellubiose:  neg Lactose:  neg Maltose:  neg Melezitose:  neg Sucrose:  neg Trehalose:  neg Mannitol:  neg Salicin:  neg Ala:  neg Arg:  neg Cys:  neg Leu:  neg Lys:  neg
    ENZYME ACTIVITY
    Enzymes: General Enzymes: Carbohydrate Enzymes: Protein Enzymes: Arylamidases Enzymes: Esters/fats
    Catalase:  neg Urease:  neg Ac-β-glcamnd:  neg α-Fucosidase:  neg α-Galactosidase:  neg β-Galactosidase:  neg α-Glucosidase:  neg β-Glucosidase:  neg β-Glucuronidase:  neg α-Mannosidase:  neg ArgDH:  neg GluDC:  neg AlanineAA:  vr GluGluAA:  neg GlyAA:  + LeuAA:  neg LeuGlyAA:  neg PyrrolidAA:  neg AlkalineP:  neg AcidP:  neg Esterase(C4):  neg EstLip(C8):  neg Lipase(C14):  neg
    METABOLITES - PRODUCTION & USE
    Fuel Usable Metabolites Metabolites Released Special Products Compounds Produced

    		Acetate:  Major(+) Propionate:  minor(+) Isobutyrate:  minor(+) Succinate:  minor(+) Isovalerate:  + H2S:  + Indole:  neg
    ANTIBIOTICS ℞
    Penicillins & Penems (μg/mL) Cephalosporins (μg/mL) Aminoglycosides (μg/mL) Macrolides (μg/mL) Quinolones (μg/mL)
    amoxicillin:  S(10; disc)
    ampicillin:  S(2; disc)
    penicillin:  S(1.5U)
    cefoxitin:  S(10; disc)
    gentamicin:  R(10; disc)
    ciprofloxacin:  R(5; disc)
    Tetracyclines (μg/mL) Vancomycin Class (μg/mL) Polypep/ketides (μg/mL) Heterocycles (μg/mL) Other (μg/mL)
    tetracycline:  S(5; disc)
    metronidazole:  S(5; disc)
    trimethoprim:  R(2.5; disc)
    clindamycin:  S(2; disc)

    References

    SPECIFIC REFERENCES FOR PYRAMIDOBACTER PISCOLENS
  • Downes2009 - Pyramidobacter piscolens gen. nov., sp. nov., a member of the phylum 'Synergistetes' isolated from the human oral cavity.
  • Huang2019 - Analysis of microbiota in elderly patients with Acute Cerebral Infarction
  • Karlsson2013 - Gut metagenome in European women with normal, impaired and diabetic glucose control
  • Ye2018 - A metagenomic study of the gut microbiome in Behcet's disease
  • ...............................
    • GUT MICROBIOME COMPILATIONS AND METASTUDIES FOR PYRAMIDOBACTER PISCOLENS
  • Byrd2020 - Stability and dynamics of the human gut microbiome and its association with systemic immune traits.
  • Hu2019 - The Gut Microbiome Signatures Discriminate Healthy From Pulmonary Tuberculosis Patients
  • Jie2017 - The gut microbiome in atherosclerotic cardiovascular disease
  • Lagier2016 - Culture of previously uncultured members of the human gut microbiota by culturomics.
  • Li2019b - Disordered intestinal microbes are associated with the activity of Systemic Lupus Erythematosus
  • PerezBrocal2015 - Metagenomic Analysis of Crohn's Disease Patients Identifies Changes in the Virome and Microbiome Related to Disease Status and Therapy, and Detects Potential Interactions and Biomarkers
  • RajilicStojanovic2014 - The first 1000 cultured species of the human gastrointestinal microbiota.
  • Wang2020a - Aberrant gut microbiota alters host metabolome and impacts renal failure in humans and rodents
  • Yang2020 - Species-Level Analysis of Human Gut Microbiota With Metataxonomics.
  • Yang2020a - Establishing high-accuracy biomarkers for colorectal cancer by comparing fecal microbiomes in patients with healthy families
  • Zeller2014 - Potential of fecal microbiota for early-stage detection of colorectal cancer
  • ...............................
    • Added: April 08, 2021